Radiation Dose Estimates for In-111 Platelets

---

	Estimated Radiation Dose (mGy/MBq)
ORGAN	mGy/MBq	rad/mCi
Adrenals	2.8E-01	1.1E+00
Brain	8.3E-02	3.1E-01
Breasts	9.0E-02	3.3E-01
Gallbladder Wall	2.7E-01	1.0E+00
LLI Wall	1.4E-01	5.0E-01
Small Intestine	1.6E-01	6.0E-01
Stomach	3.1E-01	1.1E+00
ULI Wall	1.7E-01	6.2E-01
Heart Wall	1.8E-01	6.5E-01
Kidneys	3.1E-01	1.1E+00
Liver	5.6E-01	2.1E+00
Lungs	1.6E-01	6.1E-01
Muscle	1.3E-01	4.7E-01
Ovaries	1.4E-01	5.3E-01
Pancreas	4.9E-01	1.8E+00
Red Marrow	1.7E-01	6.3E-01
Bone Surfaces	2.1E-01	7.7E-01
Skin	7.5E-02	2.8E-01
Spleen	5.2E+00	1.9E+01
Testes	9.0E-02	3.3E-01
Thymus	1.1E-01	4.2E-01
Thyroid	1.0E-01	3.7E-01
Urinary Bladder Wall	1.8E-01	6.7E-01
Uterus	1.4E-01	5.3E-01
Effective Dose Equivalent	5.1E-01 mSv/MBq	1.9E+00 rem/mCi

Based on data gathered in patients by Goodwin et al., Third Int. Radiopharm. Dosimetry Symposium, Oak Ridge, TN, 1980, p. 88-101. Assumed distribution and retention: Initial uptake:
Liver 8.5%, Spleen 23.5%
Platelets have a 9 day survival time, and then are transported to destruction sites, where they have a 10 day biological half time:
Liver 50%, Spleen 25%, Marrow 25%
After leaving the destruction sites, activity is cleared through the urinary bladder with a 6.6 day biological half time. Bladder voiding interval 4.8
hours.

Estimate calculated using phantom of Cristy & Eckerman (Report ORNL/TM-8381/V1 & V7). Bone and marrow model of Eckerman (Aspects of dosimetry of radionuclides within the skeleton with particular emphasis on the active marrow, In Fourth International Radiopharmaceutical Dosimetry Symposium; A.T. Schlafke-Stelson and E. E. Watson eds. CONF-851113, Oak Ridge Associated Universities, Oak Ridge, TN 37831, 1986. pp 514-534.) used.